# Contact Assent Peptides — Editorial Desk

> Reach the Assent Peptides editorial desk regarding citations, corrections, or research-related correspondence about the metabolic-peptide digest.

Correspondence on citations, corrections, and research-related inquiries — the things a reference desk most wants to hear about.

## Editorial correspondence

Assent Peptides welcomes correspondence on the research record: a citation quoted inaccurately, a regulatory reference that has gone out of date, or a peer-reviewed study about retatrutide or tirzepatide that should be added to the [references page](/references). Corrections that improve accuracy are the most useful messages this desk receives, and they are read carefully.

The most actionable notes specify: the page they refer to, the exact passage in question, and the supporting citation — a DOI or PubMed ID wherever possible. That lets us verify a proposed change against the source directly.

**Editorial mailbox:** editors@assentpeptides.com

## What this desk cannot do

So that no message goes unanswered for the wrong reason, some things fall outside what this site can address. Assent Peptides is a literature digest, not a clinic or vendor, so it cannot:

- Advise on, recommend, or comment on human use of any compound discussed here.
- Suggest a dose, schedule, or route of administration for any individual.
- Diagnose a condition or judge whether a research finding applies to a specific person.
- Sell, source, recommend, or help locate any compound from any supplier.
- Answer questions from athletes subject to anti-doping rules about compound use.

Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed; the mailbox is monitored intermittently.

---

Literature summaries from peer-reviewed trials. No products. No doses. No medical guidance.